TipRanks on MSN12h
Syncona’s Autolus Gains FDA Approval for Leukemia Therapy
Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...
Does fish oil protect against cancer? What we know
New research suggests that omega-3 and omega-6 fatty acids, found in fish oil, may help prevent various cancers. A study of ...
precisionmedicineonline2d
FDA Approves Autolus' CAR T-Cell Therapy Aucatzyl for B-Cell Acute Lymphoblastic Leukemia
The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.
The American Journal of Managed Care2d
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia
Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...
Cure Today2d
FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
Oncology Nurse Advisor3d
Potential New Prognostic Marker Identified in ALL
The immune system and especially the B cells of patients with acute lymphoblastic leukemia (ALL) is severely compromised following withdrawal from therapy, according to a new study. However, 6 months ...
Beigene Highlights Innovative Hematology Portfolio Across B-Cell Malignancies At ASH 2024
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across ...